TESTOSTERONE UNDECANOATE
| Brand name | TLANDO |
|---|---|
| Active ingredient | TESTOSTERONE UNDECANOATE |
| Strength | 112.5MG |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | March 2022 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 12691057 | April 2041 | product |
| 11464735 | April 2041 | product |
| 12011503 | October 2040 | product |
| 12310978 | February 2039 | use U-4194 |
| 11559530 | November 2037 | use U-1500 |
| 10716794 | November 2030 | use U-1500 |
| 9949985 | November 2030 | use U-1500 |
| 11311555 | November 2030 | use U-1500 |
| 11364249 | November 2030 | use U-1500 |
| 10226473 | November 2030 | use U-1500 |
| 9943527 | November 2030 | use U-1500 |
| 11433083 | November 2030 | use U-1500 |
| 11304960 | January 2029 | product |
| 8865695 | January 2029 | use U-1500 |
| 8778922 | January 2029 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.